OMS103HP is being developed for improvement in knee function following ACL reconstruction. Secondary benefits being evaluated include reduced postoperative pain, improvement in knee motion and earlier return to work.
Full Title of Study: “Double-Blind, Multicenter Study Evaluating the Safety of OMS103HP and Vehicle in Subjects Undergoing Anterior Cruciate Ligament Reconstruction With an Open-Label Phase Containing a PK Analysis in a Subset of Subjects”
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Study Primary Completion Date: March 2010
The anterior cruciate ligament (ACL) is an important stabilizer of the knee. Orthopedic surgeons replace the torn ligament during ACL reconstruction surgery. Surgical trauma initiates an acute inflammatory response, including swelling and pain, that leads to restricted joint motion and loss of function. Because of the dynamic nature, complexity and redundancy of the chemical mediators of inflammation and pain and their pathways, no currently available single drug has sufficiently broad spectrum of activity to effectively inhibit the inflammatory process. OMS103 provides a multicomponent approach to controlling the inflammation induced by arthroscopic surgery. It delivers three active ingredients, each with distinct pharmacological activities, directly to the site of surgical procedures to preemptively block the inflammatory cascade induced by surgical trauma.
- Drug: OMS103HP
- Maximum of 13 bags of OMS103HP irrigation solution over a maximum of 2 hours
- Drug: Vehicle
- Maximum of 13 bags of BSS irrigation over a maximum of 2 hours.
Arms, Groups and Cohorts
- Experimental: 1
- OMS103 Irrigation Solution
- Placebo Comparator: 2
- Balanced Salt Solution (BSS)
Clinical Trial Outcome Measures
- The overall incidence of adverse events regardless of relationship to study drug.
- Time Frame: 90 days
- Measures of safety and tolerability (e.g., clinical laboratory tests, physical examinations, etc.).
- Time Frame: 30 days
Participating in This Clinical Trial
- 17 – 65 years of age
- In good general health
- Undergoing arthroscopic ACL reconstruction for an ACL tear
- Allergies to any of the individual ingredients in OMS103HP
- Has open physes in the distal femur or proximal tibia
- Undergoing bilateral knee surgery
- Subject who is considered by Investigator to be an unsuitable candidate
Gender Eligibility: All
Minimum Age: 17 Years
Maximum Age: 65 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Omeros Corporation
- Provider of Information About this Clinical Study
- Gregory Demopulos, MD, CEO, CMO, Omeros Corporation
- Overall Official(s)
- Scott Houston, Study Director, Omeros Corporation
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.